



US009511059B2

(12) **United States Patent**
Bilotta et al.(10) **Patent No.:** **US 9,511,059 B2**(45) **Date of Patent:** **Dec. 6, 2016**(54) **ANTIVIRAL COMPOUNDS**(71) Applicant: **Hoffmann-La Roche Inc.**, Nutley, NJ (US)(72) Inventors: **Joseph Anthony Bilotta**, Nutley, NJ (US); **Zhi Chen**, Livingston, NJ (US); **Qingjie Ding**, Bridgewater, NJ (US); **Shawn David Erickson**, Leonia, NJ (US); **Eric Mertz**, Fair Lawn, NJ (US); **Robert James Weikert**, Basel (CH)(73) Assignee: **HOFFMANN-LA ROCHE INC.**, Nutley, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/827,762**(22) Filed: **Aug. 17, 2015**(65) **Prior Publication Data**

US 2015/0353511 A1 Dec. 10, 2015

Related U.S. Application Data

(63) Continuation of application No. 14/159,566, filed on Jan. 21, 2014, now abandoned.

(60) Provisional application No. 61/755,519, filed on Jan. 23, 2013.

(51) **Int. Cl.****C07D 249/14** (2006.01)
C07D 401/12 (2006.01)
A61K 31/4439 (2006.01)
A61K 31/4196 (2006.01)
A61K 45/06 (2006.01)(52) **U.S. Cl.**CPC **A61K 31/4439** (2013.01); **A61K 31/4196** (2013.01); **A61K 45/06** (2013.01); **C07D 249/14** (2013.01); **C07D 401/12** (2013.01)(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2004/0186288 A1 9/2004 Kruger et al.
2014/0010783 A1* 1/2014 Bilotta C07D 249/14
424/85.4

FOREIGN PATENT DOCUMENTS

WO 2007030680 3/2007
WO WO 2014/006066 * 1/2014 C07D 249/14

OTHER PUBLICATIONS


The Japanese Office Action, issued on Jul. 14, 2016, in the corresponding Japanese Application No. 2015-554113.

The Chinese Office Action, issued on Aug. 3, 2016, in the corresponding Chinese Application No. 201480005630.6.

* cited by examiner

Primary Examiner — Alicia L Otton(57) **ABSTRACT**

The present invention discloses compounds of Formula I:



wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

1 Claim, No Drawings